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Neuropeptides activate G protein-coupled receptors
to acutely modulate cellular excitability and synaptic
transmission. However, due to the lack of reagents
for precise delivery of peptides within dense brain
tissue, the spatiotemporal scale over which neuro-
peptides act is unknown. To achieve rapid and
spatially delimited delivery of neuropeptides in
mammalian brain tissue, we developed photoactivat-
able analogs of two opioids: [Leu5]-enkephalin (LE)
and the 8 amino acid form of Dynorphin A (Dyn-8).
These peptides are functionally inactive prior to
photolysis, and exposure to ultraviolet (UV) light
causes clean release of LE and Dyn-8. Recordings
from acute slices of rat locus coeruleus (LC) demon-
strated that photorelease of LE activates mu opioid
receptor-coupled K+ channels with kinetics that
approach the limits imposed by G protein-mediated
signaling. Temporally precise and spatially delimited
photorelease revealed the kinetics and ionic nature
of the mu opioid response and the mechanisms
that determine the spatial profile of enkephalinergic
volume transmission in LC.
INTRODUCTION
Neuropeptides are expressed and secreted throughout the
mammalian brain, typically in combination with a fast neuro-
transmitter such as glutamate or GABA (Ho¨kfelt et al., 2000).
Neuropeptides are packaged in vesicles and several are known
to be released in an activity-dependent manner (Ludwig and
Leng, 2006). Neuropeptide expression is often regulated by
neuronal activity and many neurons are classified by their
selective expression of different neuropeptides and neuropep-
tide receptors (Ho¨kfelt et al., 2000). Such regulated and hetero-
geneous expression of neuropeptides suggests a precise
function in neuron-to-neuron signaling. Indeed, many aspects
of synapse and cell function are modulated by neuropeptide-
dependent activation of G protein-coupled receptors (GPCRs)
(Strand, 1999; Tallent, 2008). At the behavioral level, neuro-
peptides have profound and complex neuromodulatory effectson brain function: they regulate social bonding (Insel, 2010),
feeding (Morton et al., 2006), sleep (Adamantidis et al., 2010),
aversion (Knoll and Carlezon, 2010), and reward (Le Merrer
et al., 2009).
Studies into neuropeptide systems have been limited by
a paucity of experimental tools. The conditions that trigger
neuropeptide release from neurons are largely unknown and
currently availablemethods of activating neuropeptide receptors
in brain tissue prevent quantitative studies of their function.
Although small-molecule agonists for many neuropeptide recep-
tors are available, many GPCRs exhibit functional selectivity
such that they are incompletely or unnaturally activated by
synthetic ligands (Urban et al., 2007). Furthermore, neuropep-
tides can bind and activate multiple receptor subtypes present
on the same cell with similar affinities (Lupica et al., 1992;
Svoboda et al., 1999). Thus, exogenous application of peptide
ligands, rather than synthetic agonists, more accurately mimics
endogenous peptidergic signaling. However, compared to
traditional pharmacological agents, peptides are large, hydro-
phobic molecules and thus diffuse slowly within the brain.
Direct peptide application in vivo and in brain slices by perfusion,
pressure injection (Williams et al., 1982), or iontophoresis
(Travagli et al., 1995) produces a slowly rising, prolonged,
and spatially imprecise presentation of the peptide. These
methods offer poor control over the concentration of peptide
delivered, largely limiting quantitative analysis to the effects of
saturating doses for consistency (Duggan and North, 1983).
However, such doses can rapidly trigger receptor desensitiza-
tion and internalization, which limits robustness and experi-
mental throughput. Therefore, typical peptide delivery methods
can only reveal slow and spatially imprecise neuropeptide
actions, leaving the possibility of short-lived, local neuropeptide
signaling unexplored.
In dissociated neurons, peptide signaling reaches full
activation within several seconds of agonist exposure and
deactivates within seconds of washout (Ingram et al., 1997).
However, in intact brain tissue, neuropeptide receptors are
often found up to hundreds of microns from peptide release
sites (Khachaturian et al., 1985), suggesting that neuropeptides
are capable of volume transmission. Indeed, there is strong
evidence that this phenomenon occurs in the spinal cord
(Duggan, 2000). The spatiotemporal extent of neuropeptide
signaling is determined by the poorly understood interactions
of rapid GPCR signaling downstream of ligand binding, slow
peptide diffusion, and the action of extracellular peptidases,Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc. 249
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Figure 1. CYLE and CYD8 Are Caged LE and Dyn-8
Analogs, Respectively
(A) One-letter-code amino acid sequences of LE, Dyn-8,
and the CNB-modified analogs CYLE and CYD8.
(B) Chemical structure of CYLE. The CNB moiety is drawn
in red.
(C) Dose-response curves for LE (black squares), CYLE
(blue triangles), and LE in 100 nM CYLE (open squares) at
delta (left) and mu (right) opioid receptors. The solid lines
depict the best-fit sigmoidal functions used to derive the
EC50 values reported in the text. The dashed lines are fits
to the data obtained by adding caged compound to the
parent-peptide dilution series and demonstrate the lack of
antagonist by the caged compound. Data were normalized
to the maximal responses produced by the endogenous
peptide agonists and are expressed as the mean ± SEM.
(D) As in C, but showing the dose-response curves for
Dyn-8 (black squares), CYD8 (green triangles), and Dyn-8
in 100 nM CYD8 (open squares) at kappa (left) and mu
(right) opioid receptors.
Neuron
Photoactivatable Opioidsleaving the limits of neuropeptide signaling in the brain
undefined.
In order to overcome these technical limitations and gain
insight into the spatiotemporal dynamics of peptidergic
signaling, we have developed a strategy to produce photoacti-
vatable neuropeptides that can be applied to brain tissue at
high concentrations in an inert form. These molecules can be
rapidly photolyzed to trigger release of the endogenous neuro-
peptide with high temporal and spatial precision (Ellis-Davies,
2007). Our initial efforts focus on opioid neuropeptides, since
these short peptides and their receptors are known to regulate
pain sensation (Scherrer et al., 2009), behavioral reinforcement
(LeMerrer et al., 2009), and addiction (Gerrits et al., 2003). Opioid
peptides and their receptors are prominent in many brain
regions, including hippocampus, cerebellum, striatum, amyg-
dala, and the locus coeruleus (Khachaturian et al., 1985;
Mansour et al., 1994). The opioid receptor family consists of
three classically recognized receptors: mu, delta, and kappa.
These are activated with differential affinity by the endogenous
opioid peptides enkephalin and dynorphin, and all couple to
Gai/o such that their activation typically inhibits electrical
excitability and neurotransmitter release via the opening of K+
channels and inhibition of voltage-gated calcium channels (Wag-
ner and Chavkin, 1995).
To enable rapid, spatially delimited delivery of opioid peptides
in neural tissue, we have developed ‘‘caged’’ LE and Dyn-8
peptides that can be released by exposure to UV light. These
peptide analogs contain a photolabile chemical moiety in a posi-250 Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc.tion that attenuates activity at opioid receptors.
Exposure to light causes the blocking group to
detach, thereby releasing the peptide agonists.
As photolysis occurs with microsecond kinetics,
release can be initiated on the timescale of
neurotransmission. Importantly, the concentra-
tion and spatial extent of released peptide can
be regulated by varying laser power and the
area of illumination. We characterized thesetools in brain slices and used them to define the spatiotemporal
dynamics of opioid signaling with unprecedented resolution.
RESULTS
Design of Photoactivatable Opioid Neuropeptides
Enkephalins and dynorphins are the most prominent opioid
peptides in the brain (Khachaturian et al., 1985). We chose to
work with LE and Dyn-8 (Figure 1A) because they are the small-
est and most chemically stable endogenous opioids from these
peptide families. LE activates delta andmu opioid receptors with
nanomolar affinity but is inactive at kappa receptors (Toll et al.,
1998). The three additional C-terminal amino acids found in
Dyn-8 confer nanomolar potency at kappa receptors in addition
to mu and delta receptors (Toll et al., 1998). To render these
peptides inactive until exposed to light, we produced analogs
modified at the N-terminal tyrosine side chain with the carboxy-
nitrobenzyl (CNB) chromophore, which photoreleases tyrosine
with high quantum yield (0.3) (Sreekumar et al., 1998) on the
microsecond timescale (Tatsu et al., 1996) (see Supplemental
Information, available online, for information on peptide produc-
tion and handling). Extensive studies into the structure-activity
relationships of enkephalins (Morley, 1980) and dynorphins
(Chavkin and Goldstein, 1981) have revealed an essential role
for their common N-terminal tyrosine (Y) in receptor activation.
In particular, alkylation (Beddell et al., 1977) or removal (Terenius
et al., 1976) of the phenolic OH group reduces the potency of
enkephalin analogs, suggesting that modification of the tyrosine
Neuron
Photoactivatable Opioidsside chain of LE and Dyn-8 may be a viable caging strategy.
Based on these considerations, we designed CNB-Y-[Leu5]-
enkephalin (CYLE) and CNB-Y-Dyn-8 (CYD8) (Figure 1A) to
release LE and Dyn-8, respectively, in response to illumination
with UV light. The chemical structure of CYLE is shown in Fig-
ure 1B. Reverse-phase high-pressure liquid chromatography
experiments confirmed that both peptides cleanly photorelease
their parent peptides in pH 7.4 phosphate-buffered saline in
response to 355 nm laser illumination (Figure S1) and that they
are stable in the dark at room temperature for >48 hr (data not
shown).
Activity of CYLE and CYD8 at Opioid Receptors
To determine whether CYLE and CYD8 are inactive at opioid
receptors prior to photolysis, we compared their activity on
opioid receptors relative to that of LE and Dyn-8, respectively,
using an in vitro functional cellular assay. To detect opioid
receptor activation, we utilized HEK293 cells that stably express
a Gas-Gai chimera (S.D. Liberles and L.B. Buck, personal
communication). This chimeric protein allows GPCRs that
normally do not signal through Gas to stimulate adenylate
cyclase and control the transcription of a cAMP-dependent
reporter construct. Cells were cotransfected with the opioid
receptor of interest and the reporter construct such that
receptor activation leads to production of secreted alkaline
phosphatase (SEAP). The amount of SEAP that accumulates
in the media is assayed on a fluorescence plate reader with
the fluorogenic substrate 4-methylumbelliferone phosphate
(Liberles and Buck, 2006).
Using this assay, we obtained dose-response curves for CYLE
and CYD8 at mu, delta, and kappa opioid receptors and
compared those to the actions of the parent peptides (Figures
1C, 1D, and S2). The potency of CYLE was reduced 100- to
500-fold with respect to LE at both delta (LE EC50, 3.2 ±
0.8 nM; CYLE EC50, 1.7 ± 0.4 mM) and mu receptors [LE EC50,
90 ± 11 nM; CYLE EC50, 16 ± 1.7 mM (Figure 1D)]. Similar to
LE, CYLE did not activate kappa receptors (Figure S2), and the
presence of 100 nM CYLE did not reduce the affinity of LE at
mu and delta receptors (Figure 1C) or that of Dyn-17 at kappa
receptors (Figure S2), indicating that CYLE does not act as an
antagonist. CYD8 exhibited similar reductions in potency in
comparison to Dyn-8 at kappa (Dyn-8 EC50, 7.1 ± 0.8 nM;
CYD8 EC50, 16 ± 1.7 mM), mu [Dyn-8 EC50, 63 ± 4.4 nM; CYD8
EC50, 23 ± 2.6 mM (Figure 1D)], and delta receptors [Dyn-8
EC50, 9.6 ± 2.3 nM; CYD8 EC50, 3.9 ± 0.6 mM (Figure S2)], with
no indications of antagonism. Summary dose-response data
are tabulated in Table S1. These data reveal that CYLE and
CYD8 possess no significant agonist or antagonist activity at
concentrations that should strongly activate receptors following
photolysis.
Photorelease of Opioids in Brain Slices
In order to characterize the ability of these molecules to activate
neuropeptide receptors in brain slices with spatiotemporal
precision, we took advantage of the well-described opioid-
receptor-mediated activation of K+ channels in neurons of the
locus coeruleus (LC). The LC is heavily innervated by enkephali-
nergic afferents (Curtis et al., 2001; Drolet et al., 1992), and LCneurons express a high density of mu opioid receptors in their
somata and dendrites (Van Bockstaele et al., 1996a, 1996b),
activation of which pauses spontaneous firing (Pepper and
Henderson, 1980) by producing large outward currents (Travagli
et al., 1995, 1996; Williams et al., 1982), at least in part through G
protein-coupled inward rectifier K+ (GIRK) channels.
We obtainedwhole-cell recordings from neurons in acute hori-
zontal slices of rat LC (Figure 2A) and characterized the ability of
CYLE to photoactivate mu receptors by releasing LE. In current-
clamp recordings, these cells spontaneously fired action poten-
tials at 2–8 Hz, while local perfusion of 10 mMLE caused a strong
hyperpolarization and transient pause in spiking (Figure 2B),
consistent with previous studies (Williams et al., 1982).
In voltage-clamp recordings at a holding potential of 55mV,
application of 10 mM LE via a perfusion pipette placed near the
cell of interest evoked average (n = 6) outward currents of
199 ± 23 pA in amplitude (Figure 2C). In contrast, when applied
to the same cells, 10 mM CYLE evoked an average outward
current of 5.6 ± 4 pA, measured 3.5–4 min after addition to the
circulating artificial cerebrospinal fluid (ACSF) (Figure 2C). A
subsequent uncaging stimulus consisting of a 5 ms flash from
a 124-mm-diameter beam of 355 nm light induced a large
outward current that was blocked by the addition of 2 mM
naloxone (Nal), a broad-spectrum opioid receptor antagonist
(Figure 2D). Additionally, photolysis of an isomer of CYLE in
which the amino acid sequence was scrambled to render it inac-
tive at opioid receptors did not produce currents (Figure S3).
To evaluate the extent and kinetics of photoactivation, we
compared responses (n = 6) evoked by local application of
10 mM LE and a subsequent UV light flash in the presence of
10 mMCYLE (Figure 2E). This analysis revealed that photorelease
of LE produces currents similar in amplitude to those evoked by
the same concentration of locally applied LE (peak current =
207 ± 19 pA versus 179 ± 9 pA for local perfusion and photolysis,
respectively) (Figure 2F). Nevertheless, consistent with rapid
delivery of LE directly to the recorded cell, the onset kinetics of
the light-evoked response were nearly two orders of magnitude
faster than for local perfusion (ton = 349 ± 26 ms versus 11.64 ±
2.22 s for photolysis and local perfusion, respectively) (Figure 2F),
such that the peak current was reached within 1–2 s after the
light flash. In contrast, the kinetics of deactivation for the
uncaging responsewere only2-fold faster (toff = 24 ± 2 s versus
14 ± 1 s for local perfusion and photolysis, respectively) (Fig-
ure 2F). Additionally, the responses to 15 uncaging stimuli deliv-
ered to the same cell once every 3 min were stable (Figure 2G).
Thus, CYLE enables rapid and robust delivery of enkephalin in
brain slices.
One advantage of caged compounds is the ability to photore-
lease molecules in a graded or analog fashion by varying the
amount of photolysis light. This can be readily achieved by
manipulating the light intensity or the area of illumination. To
explore the former approach, we applied 5 ms flashes of
a focused, 30-mm-diameter spot of UV light to the soma during
voltage-clamp recordings and varied the light intensity. Under
these conditions, the light-evoked currents in individual cells
increased in amplitude with light power (Figure 3A) such that
the average (n = 8) peak currents ranged from 31 ± 3 pA at
1 mW to 300 ± 32 pA at 91 mW.Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc. 251
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Figure 2. Rapid Activation of Outward Currents in
Neurons of LC in an Acute Brain Slice by Photore-
lease of LE
(A) Left: Dodt contrast image of an acute horizontal
brainstem slice that contains the LC. The 4th ventricle is
marked (4V). Right: magnified image of the boxed region in
the left image.
(B) Silencing of spontaneous action potentials in a LC
neuron by local perfusion of LE.
(C) Left: outward currents in an LC neuron, resulting
from application of LE (black bar) and CYLE (gray bar).
Right: average peak amplitudes of currents triggered by
LE (black) and CYLE (gray) (n = 6 cells). Data are ex-
pressed as the mean ± SEM. Asterisk denotes a sig-
nificant difference from local perfusion of 10 mM LE
(p < 0.05).
(D) Left: outward current in an LC neuron bathed in
10 mM CYLE evoked by a 5 ms flash of UV light in the
absence (purple) or presence (blue) of the opioid antago-
nist Naloxone (Nal). The uncaging stimulus was applied
at the time indicated by the arrowhead. Right: average
peak amplitudes of UV-light-evoked currents in each
condition (n = 3 cells). Asterisk denotes a significant
difference from photolysis in the absence of Naloxone
(p < 0.05).
(E) Overlay of currents from an LC neuron in response
to local application of LE (black) and to an uncaging
stimulus (purple) in the presence of 10 mM CYLE. The
local perfusion experiment was sampled at 0.5 Hz. Each
data point represents the average current during a 1 s
acquisition.
(F) Average peak amplitudes (left), ton (middle), and toff (right) of currents evoked by local application of 10 mM LE (black) or an uncaging stimulus in the presence
of 10 mM CYLE (purple, n = 6 cells). Asterisk denotes a significant difference from local perfusion of 10 mM LE (p < 0.05).
(G) Individual baseline-normalized responses from 15 uncaging stimuli applied every 3 min to the same cell. The time between episodes is omitted for
clarity.
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Photoactivatable OpioidsAnother approach to analog delivery is to vary the area of illu-
mination. This was achieved by shaping a collimated beam
of fixed power density with a field diaphragm placed in the laser
path at a location conjugate with the image plane. The area of the
field of illumination was varied from 250 mm2, which is smaller
than a typical LC cell body, to 12 3 103 mm2, which covers the
soma and a large region of the proximal dendrites (Figure 3B).
Responses were measured in both voltage- and current-clamp
(Figure 3C). In voltage-clamp, varying the area of illumination
produced light-evoked outward currents of various magnitude
(peak current = 178 ± 29 pA versus 18 ± 6 pA for 12 3 103 mm2
and 250 mm2 fields, respectively) and duration. In current clamp,
the same uncaging stimuli produced pauses in spontaneous
firing of graded duration (t = 29 ± 5 s versus 4 ± 0.3 s for 12 3
103 mm2 and 250 mm2 fields, respectively) and hyperpolarizations
of graded amplitude. In individual cells and across cells, the
responses to each photolysis condition in both recording config-
urations were tightly correlated (Figure 3D). Furthermore, the
onset kinetics of the light-evoked currents did not vary across
the different uncaging stimuli (ton = 349 ± 26 ms versus 400 ±
66 ms versus 417 ± 112 ms for 12 3 103 mm2, 4.2 3 103 mm2,
and 1.2 3 103 mm2 fields, respectively; one-way ANOVA p =
0.81; kinetics could not be reliably measured for responses to
the 250 mm2 uncaging stimulus). These results indicate that
photolysis delivers LE directly to the site of action over a range
of areas.252 Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc.The Ionic Basis of Enkephalin-EvokedOutwardCurrents
The ability to tightly regulate the area over which LE is applied
provides an opportunity to study the ionic conductances that
underlie the mu opioid response in LC with unprecedented
accuracy. Although it has been clearly demonstrated that mu
opioid receptor activation opens GIRK channels in LC neurons
(Torrecilla et al., 2002), reversal potentials determined for the
evoked currents in brain slices are frequently much more
negative (140mV to 120mV) than predicted for a pure K+
conductance according to the Nernst equation (105mV, typi-
cally). This observation might be accounted for by the inability to
voltage-clamp currents generated in the large (Shipley et al.,
1996), gap-junction-coupled dendrites (Ishimatsu and Williams,
1996; Travagli et al., 1995) of LC neurons. Several studies
suggest that inhibition of a standing, voltage-insensitive Na+
current may contribute 50% of the observed outward current
response to enkephalin (Alreja and Aghajanian, 1993, 1994).
Thus, the complete ionic nature of the enkephalin-evoked
outward currents has been a subject of debate (Alreja and Agha-
janian, 1993, 1994; Osborne and Williams, 1996; Torrecilla et al.,
2002; Travagli et al., 1995).
To address this issue, we measured the reversal potential of
the LE evoked outward current while restricting the uncaging
area to the soma and proximal dendrites where voltage clamp
is expected to be optimal (Williams and Mitchell, 2008). Impor-
tantly, the responses to the uncaging stimuli shown in Figure 3B
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Figure 3. Graded Activation of Outward Currents in LC Neurons
Evoked by Photorelease of LE
(A) Left: currents measured in an LC neuron in response to uncaging
stimuli using a 30 mm spot of light focused on the soma at powers ranging
from 1 (black) to 91 mW (red). Right: average peak amplitudes of currents
evoked at different laser powers (n = 6 cells). Data are expressed as the
mean ± SEM.
(B) Reverse-contrast two-photon laser scanning microscopy image of an LC
neuron filled with Alexa Fluor-594. The colored rings and corresponding
legend indicate the various diameters of a collimated photolysis beam.
(C) Current (top) and voltage (bottom) responses of an LC neuron evoked by
uncaging over the areas depicted in (B).
(D) Average peak current amplitude (left axis, squares) and action-potential
pause duration (right axis, circles) as a function of uncaging spot diameter.
Circles are offset slightly to the right for clarity.
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Photoactivatable Opioidswere not significantly attenuated by the gap junction inhibitor
carbenoxolone (Figure S4), suggesting that gap junctions do
not contribute to the LE-mediated currents evoked by uncaging
CYLE around the soma. To measure reversal potentials in the
voltage range of a K+ conductance, we held cells at 55mV
and applied negative voltage ramps to 140mV over 500 ms
during the peak of the outward current (Figure 4A). A response
to the ramp alone is presented with a response to the ramp
after an uncaging stimulus corresponding to the 4.2 3 103 mm2
beam (the green ring in Figure 2B) in Figure 4B. The average
(n = 12) LE-evoked current (Figure 4C, black trace) was isolated
by subtracting the baseline from the light-evoked response.
After correction for the junction potential, this current reversed
at 107.2mV ± 1.8mV (Figure 4D), closely matching the calcu-
lated K+ reversal potential of 106mV ([K+]out = 2.5 mM,([K+]in = 145 mM). In the presence of 3.5 mM BaCl2, a GIRK
channel blocker, the outward current was largely attenuated
and only a small response remained (peak current = 142 ±
17 pA versus 29 ± 4 for control and 3.5 mM BaCl2, respectively).
The average (n = 13) LE-evoked, Ba2+-insensitive current (Fig-
ures 4C and D), appeared to reverse near 140mV. We were
unable to block or occlude this residual outward current with
the voltage-sensitive Na+ channel blocker tetrodotoxin (TTX),
the voltage-gated K+ channel blocker 4-AP, the voltage-gated
Ca2+ channel blocker Cd2+, or the hyperpolarization-activated
cyclic-nucleotide-gated channel blocker ZD7288 and it per-
sisted in K+-free, Cs+-based internal (data not shown). Thus,
at least 80% of the outward current evoked by LE at the
soma and proximal dendrites is carried by a Ba2+-sensitive K+
current.
The finding that somatodendritically evoked currents reverse
in the predicted range for a K+ conductance suggests that
dendritic currents may indeed account for the negatively shifted
reversal potentials previously obtained with bath-applied
enkephalin. Therefore, using a focused, 30 mm uncaging spot,
we compared the reversal potential of currents evoked by
uncaging on the soma and 150–200 mm away on a dendritic
branch. Because the dendritic current was typically much
smaller than the somatic current evoked by a given uncaging
stimulus, we also measured the somatic current after reducing
laser power to produce a response of similar amplitude. As
shown for a representative cell in Figure 4E, whereas somatically
evoked currents of different amplitude reverse at the same
membrane potential, the reversal potential of the dendritically
evoked current is shifted to more negative values. In two of
five cells, the reversal potential was shifted by 12mV and
16mV, but evoked currents in the other three cells did not
reverse even at 140mV, the most negative potential reached
in our ramps. For quantification purposes, these were assigned
a reversal potential of 140mV. By this measure, the average
(n = 5) large somatic currents (182.4 ± 8.5 pA), small somatic
currents (63.4 ± 5.9 pA), and dendritic currents (59.6 ± 4.3 pA;
p = 0.71, paired two-tailed t test between small somatic
and dendritic currents) reversed, respectively, at 110.4mV ±
1.9mV, 109.2mV ± 1.6mV, and 132.2mV ± 4.8mV (p < 0.05,
paired two-tailed t test between small somatic and dendritic
currents). Thus, opioid-activated currents in the dendrites of
LC neurons cannot be reversed by somatic voltage clamp in
the membrane potential range expected for K+ currents.
Proteolytic Contribution to Enkephalin Clearance in LC
Although neuropeptides are generally thought to be degraded
by extracellular proteases, the extent to which this clearance
mechanism limits the duration of peptide signaling after release
is unknown. To determine the contribution of peptide degrada-
tion via proteolysis to the termination of enkephalin signaling,
we repeated the voltage-clamp experiment shown in Figure 3B
and compared the currents evoked by light before and after
the addition of the peptidase inhibitors bestatin and thiorphan
(Figure 5A). This inhibitor combination blocks the degradation
of enkephalin in brain tissue by >95% and increases the EC50
of bath-applied [Met5]-enkephalin by 7-fold in LC (Williams
et al., 1987). When the uncaging beam was restricted to theNeuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc. 253
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Figure 4. Activation of K+ Currents by LE
(A) Voltage-ramp protocol for measuring K+ currents.
(B) Currents from an LC neuron in response to the voltage-
ramp protocol in the absence (black) and presence of an
uncaging stimulus (purple).
(C) Average isolated responses to the uncaging stimulus
and voltage ramp in the absence (black, n = 12 cells) and
presence (blue, n = 13 cells) of the GIRK blocker BaCl2.
The dotted line indicates the baseline current in the
absence of LE signaling. Average traces are shown as the
mean (line) ± SEM (shaded regions).
(D) Average current-versus-voltage plot for the average
currents shown in (C) indicate that the reversal potential
corresponds to the calculated reversal potential of K+.
(E) Current-versus-voltage plot for the currents generated
by the indicated uncaging stimuli in an individual LC
neuron.
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Photoactivatable Opioidssoma (250 mm2 and 1.2 3 103 mm2 beam areas), no significant
differences were observed in the peak current, charge transfer,
or the time at which half of the total charge transfer occurs
(TQ50%) (Figure 5B). This indicates that when opioids are
released with spatial heterogeneity, the local response is deter-
mined by the local time course of peptide release and diffusion,
without contribution of peptidase-mediated degradation.
However, with larger uncaging areas, peptidase inhibition signif-
icantly enhanced all of these parameters. The total charge trans-
fer at the largest area examined was particularly sensitive to this
manipulation, as it was enhanced 1.8-fold, while the TQ50%was
enhanced 1.6-fold. The TQ50% was used to quantify the deac-
tivation time course, because the decay kinetics in peptidase
inhibitors were not well fit by a monoexponential, as expected
from the complex kinetics of buffered-diffusion reactions. These
results indicate that peptidases limit the spread of enkephalin
signaling when released in large volumes but that diffusion plays
a larger role in limiting the spread from spatially confined release
sites.A
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To determine the spatial precision withwhich LE can signal in LC,
we focused the photolysis beam down to a nominal spot of
2 mm in diameter and measured the current responses as the
uncaging stimulus was applied at various distances along
a straight line from the cell body. Due to strong scattering of
UV photons by brain tissue, the effective illumination spot will
be larger (Sarkisov and Wang, 2007). Laser power was adjusted
to elicit a response of 100 pA upon photolysis at the soma.
Although care was taken to choose a trajectory that avoided
major dendritic branches, due to the somewhat radial nature of
the dendrites in the x-y plane, dendritic processes were typically
present near the uncaging stimulus and most likely contributed
to the measured responses. Nonetheless, the flash-evoked
current amplitudes decreased with distance from the soma (Fig-
ure 6A), yielding a half-maximal response at a distance of
100 mm. The activation kinetics of the evoked currents similarly
decreased with distance from the soma (ton = 0.31 ± 0.01 s
versus 0.89 ± 0.14 s for photolysis at the soma and at a distance*
*
PIsrol
Figure 5. Effect of Peptidase Inhibitors on Light-
Evoked Currents
(A) Average (n = 5 cells) responses to the uncaging stimuli
before (colors) and after (gray) addition of the peptidase
inhibitors. The control-condition traces are color-coded to
indicate the uncaging beam area as in Figures 3B–3D.
Average traces are shown as the mean (line) ± SEM
(shaded regions).
(B) Peak amplitude (left), total charge transfer (middle), and
time to 50% charge transfer (TQ50%, right) of the
responses evoked by the uncaging stimuli for each cell in
basal control conditions and after addition of peptidase
inhibitors (PIs). The average population data are also
shown (solid circles) as the mean ± SEM. Asterisk denotes
a significant difference from control (p < 0.05). The small
currents generated in response to the two smallest un-
caging stimuli did not allow reliable calculation of TQ50%.
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Figure 6. Spatial Extent of LE Signaling
(A) Left: currents in an LC neuron evoked by a focused 2 mm spot of UV light at
various distances from the soma. Right: the average peak amplitudes (n = 9
cells) of evoked currents as a function of distance from the soma. Data are
expressed as the mean ± SEM.
(B) Rising phases of the average currents (left) and quantification of the time
constants of activation (ton, right) (n = 9 cells), showing faster activation
kinetics for stimuli delivered near the soma.
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Photoactivatable Opioidsof 150 mm, respectively; Figure 6B). Kinetic parameters could not
be derived from the small individual responses to the uncaging
stimulus at a distance of 300 mm and were thus excluded
from this analysis. To determine whether the observed profile
depends on the shape of the uncaging stimulus (in this case
a cone of light focused to a 2-mm-diameter spot), we repeated
this experiment using a collimated beam of 10 mm in diameter
and adjusted the light intensity to again produce a response of
100 pA at the soma. As shown in Figure S4, the spatial profiles
for the elicited currents are superimposable, suggesting that the
spatial extent of signaling observed reflects the spread of
enkephalin signaling and is not a consequence of the optical
configuration used for uncaging.
DISCUSSION
Neuropeptides are an important class of neurotransmitters that
has received relatively little attention in comparison to other
neuromodulators such as acetylcholine and the monoamines.
Because it has been difficult to selectively stimulate neuropep-
tide release from distinct cell types (however, see Ludwig and
Leng [2006]), our understanding of neuropeptide signaling
dynamics is limited. Photoactivatable molecules enable spatio-
temporally precise delivery of endogenously occurring ligands
in relatively intact brain-tissue preparations. We were able to
generate photoactivatable opioid neuropeptides that are suffi-
ciently inert to allow large responses to be generated with a brief
uncaging stimulus. The caged LE analog CYLE provided robust,
rapid, and graded delivery of LE in acute brain slices. The ability
to spatially restrict release allowed us to selectively evoke
currents from regions of neurons that can be effectively voltageclamped in order to accurately measure the reversal potential of
the mu-opioid-receptor-mediated K+ current, which was not
previously possible in brain slices of LC. These features further
enabled us to quantitatively characterize the mechanisms
governing peptide clearance and delineate the spatial profile of
enkephalinergic volume transmission for the first time.
Based on extensive prior pharmacology, we identified the
N-terminal tyrosine side chain as a caging site where the rela-
tively small CNB chromophore sufficiently attenuates potency
on both LE and Dyn-8. Peptides may be inherently more difficult
to ‘‘cage’’ than small molecules, as the caging group will only
interfere with one of multiple interaction sites with receptors.
In particular, hydrophobic interactions contribute greatly to
peptide-receptor binding, and hydrophobic side chains lack
functional handles for attaching caging groups. For these rea-
sons, the full-length Dyn-17 or beta-endorphin may be more
difficult to cage by the same approach.
CNB-tyrosine photolysis occurs with microsecond kinetics
following a light flash (Sreekumar et al., 1998; Tatsu et al.,
1996). Thus, the time course of activation we observed in slices
likely reflects the time required for ligand binding and engage-
ment of the G protein-mediated signaling pathway that activates
GIRK channels. Indeed,we observed a 50–100msdelay from the
flash to the current onset and a peak response within 1–2 s,
which closely matches the rates observed for GABABR-medi-
ated GIRK activation in dissociated cells using rapid perfusion
techniques (Ingram et al., 1997; Sodickson and Bean, 1996).
However, the offset kinetics we observed are orders of magni-
tude slower than those measured in dissociated cells, where
currents cease within 1–2 s of agonist washout. Instead, photo-
release produced deactivation kinetics that were only 2-fold
faster than those obtained with local perfusion, likely reflecting
slow diffusion of released peptide away from the recorded cell
in neural tissue and concomitant proteolytic cleavage. Indeed,
addition of a protease inhibitor cocktail slowed deactivation of
the response to photolysis over large areas.
Prompted by the ability to spatially confine LE release, we re-
visited previous studies into opioid actions on rat LC neurons
that were unable to unambiguously identify a K+ current using
reversal potential measurements in brain slices (Osborne and
Williams, 1996; Travagli et al., 1995). The reversal potential of
the LE-dependent current that we measured is accounted for
by a pure K+ current and 80% of the outward current was
blocked by a high concentration of Ba2+, consistent with a domi-
nant role of GIRKs. It has also been proposed that downregula-
tion of a cAMP-dependent standing Na+ current contributes
50% of the opioid response in rat LC (Alreja and Aghajanian,
1993, 1994). Although we cannot rule out that this component
mediates the remaining 20% of the current not sensitive to
Ba2+ or that this Na+-permeable channel may be enriched in
the dendritic regions not activated by the somatodendritically
restricted uncaging stimulus, our results clearly demonstrate
that the majority of the current in the soma and proximal portions
of the dendrites is carried by K+ channels and thus cannot reflect
the closing of Na+ channels. Consistent with previous work that
suggests that poor voltage clamp of K+ currents originating in LC
dendrites may underlie the apparent negative shift in K+ reversal
potential (Ishimatsu and Williams, 1996; Travagli et al., 1995),Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc. 255
Neuron
Photoactivatable Opioidsphotorelease of LE in the distal dendrites evoked currents that
reversed at membrane potentials much more negative than
somatically evoked currents. This shifted membrane potential
can arise from poor space clamp of the large LC dendrites, K+
currents activated in unclamped and gap-junction-coupled
neighboring cells, or from other dendritically localized and opioid
modulated conductances.
By varying the laser power and uncaging area used to photo-
release LE, we found a correlation between the amplitude and
duration of the outward current in voltage clamp and the duration
of the pause in spontaneous firing recorded in current clamp
(Figure 3). The responses to the smallest stimuli demonstrate
that small outward currents near the detection limit are sufficient
to prevent just a few action potentials without causing significant
hyperpolarization. At the opposite extreme, strong uncaging
causes a large somatic hyperpolarization and pauses action
potential firing for 30 s or longer. Thus, the effect of enkephalin
on LC firing can be subtle or dramatic, highlighting that neuro-
peptides are capable of temporally precise actions in addition
to slow volume transmission.
We found that LE could generate opioid-receptor-mediated
currents when released 150 mm from the recorded cell. The
slower-onset kinetics observed when LE was released at
locations distant from the soma suggest that the photolyzed
peptide diffused from the release site to activate receptors on
the soma and proximal dendrites. These distances are large
compared to those over which fast-acting neurotransmitters
such as glutamate (Carter et al., 2007) and GABA (Chalifoux
and Carter, 2011) can spread, as clearance mechanisms for
these neurotransmitters are present at high density in neural
tissue. Under the conditions of our experiments, LE was nearly
inactive when released 300 mm from the soma, which reflects
the limit of detection by mu opioid receptors due to dilution of
the peptide as it diffuses away from the release site. Assuming
a diffusion-limited process, this absolute boundary depends
not only on the initial quantity released, but also on the affinity
of the receptor for the ligand. Our results may overestimate
the mobility of LE in LC due to activation of receptors on
dendrites that are closer to the release site than the soma and
contributions from currents originating in gap-junction-coupled
neurons. Nonetheless, our results indicate that enkephalin can
effectively function as a volume transmitter in LC and define
the spatial profile of the spread of enkephalinergic signaling
from a single release site. The spatial profile of signaling may
be different in other brain regions due to variations in the densi-
ties and identities of proteases and possible differences in diffu-
sional mobility.
Although we obtained similar results using two differently
shaped photolysis beams, UV light scatters extensively in brain
tissue. Studies in which similar spot sizes (10–25 mm) were
employed for UV uncaging of glutamate in brain slices report
25–50 mm lateral resolution (Katz and Dalva, 1994; Kim and
Kandler, 2003). Below the surface of the brain slice, light scat-
tering enlarges the photolysis spot by approximately 2-fold in
the x-y dimensions (Sarkisov and Wang, 2007), consistent with
these observations. Because one-photon uncaging provides
poor spatial control in the z-dimension, it is most practical to
consider our results in terms of area of photolysis in the plane256 Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc.of the recorded cell. Thus, we estimate that the 10-mm-diameter
collimated uncaging stimulus illuminates an area of300 mm2 at
the depth of our recordings. At the light intensity employed, LE
evoked substantial currents when released 150 mm from the un-
caging site within 1–2 s of the light flash, indicating that the
enkephalin signal rapidly spreads through at least 70,000 mm2
of tissue, which is 200-fold greater than the area of origin. To
more accurately address peptide mobility in brain tissue, two-
photon sensitive caging groups must be employed so that
release will be restricted to mm3-scale volumes.
Here, we have described photoactivatable tools for the study
of opioid signaling within the mammalian brain. By caging both
LE and Dyn-8, we provide reagents that can be used to study
mu, delta, and kappa receptors. Using UV-mediated photolysis
of caged LE in brain slices, we demonstrated that somatic mu
receptors in the LC generate an outward current mediated
primarily by K+ channels. These reagents allowed us to probe
the mechanisms that regulate the spread of opioid signaling in
brain tissue and revealed that with graded, temporally precise,
and spatially confined release, neuropeptides are capable of
subtle and relatively short-lasting modulation of neuronal func-
tion. This approach represents a general strategy for probing
the spatiotemporal dynamics of neuropeptides and should be
applicable to other peptide transmitters.
These reagents are expected to interfacewell with two-photon
Ca2+ and voltage imaging methods, as the CNB chromophore
exhibits poor sensitivity to two-photon excitation. Similarly,
one-photon excitation, with the visible wavelengths used to
image fluorophores such as GFP and activate light-sensitive
ion channels such as channelrhodopsin, is also compatible
with our probes. However, the intense UV light used for uncaging
can photobleach fluorophores and partially activate channelrho-
dopsin, so care must be taken to control the area of illumination
and minimize the requisite UV light intensity in these contexts.
Extension to in vivo studies, including amperometry to measure
the effects of opioids on monoamine release, should be possible
by equipping optrodes and fiberoptic coupled carbon fibers with
perfusion lines for peptide delivery and may thus enable spatio-
temporal studies into opioidergic modulation of behavior with
unprecedented precision.EXPERIMENTAL PROCEDURES
Peptide Synthesis, Purification, and Stock Preparation
Custom chemical synthesis was carried out by Peptech Corporation (Burling-
ton, MA) using standard Fmoc-based solid-phase peptide synthesis. The
carboxynitrobenzyl-modified tyrosine was prepared by modifying established
protocols (Sreekumar et al., 1998). After arrival, CYLE and CYD8 were typi-
cally handled under lighting filtered using Rosculux #312 Canary optical filter
paper to remove any traces of UV light that could lead to unintentional
photolysis. It was essential to further purify the synthetic material by semipre-
parative reverse-phase high-pressure liquid chromatography (RP-HPLC,
Agilent) to remove contaminating photolysis products, which typically
included 1% LE or Dyn-8. Crucially, the UV (and VIS) lamps on the detector
were turned off during the purification to prevent photolysis of the purified
material. Purified solid material was dissolved in 50% DMSO/water and
diluted to a concentration of 10 mM. Stock concentrations were determined
by UV/VIS spectroscopy using an extinction coefficient of 1,000 M1 cm1
at 355 nm for the carboxynitrobenzyl-modified tyrosine (Sreekumar et al.,
1998).
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A 100 ml sample of either 1 mM CYLE or CYD8 in phosphate-buffered saline,
pH 7.2, contained in a quartz cuvette, was placed for 30 s in the path of
a 100 KHz pulsed q-switched UV laser (DPSS, Santa Clara, Ca) producing
800 mW of 354.7 nm light. The samples were then analyzed by RP-HPLC
on a 4.6 mm 3 150 mm Zorbax SB-C8 column (5 mm particle size) in H2O,
MeCN, 0.1% TFA at 1 ml/min. LE and CYLE were resolved by a gradient
from 30% to 70% MeCN over 10 min. Dyn-8 and CYD8 were resolved by
a gradient from 25% to 70% MeCN over 10 min. Samples were monitored
at 210 nm, 280 nm, and 350 nm. Nonphotolyzed CYLE, CYD8, LE, and Dyn-
8 samples were prepared and run under the same conditions. Although addi-
tion of the parent peptides to photolyzed samples increased the product peaks
as expected, further analysis by mass spectrometry confirmed photolytic
conversion of CYLE to LE and CYD8 to Dyn-8 (data not shown).
Cell Culture and SEAP Assay
HEK293 cells stably transfected with a chimeric Gs-Gi protein (S.D. Liberles
and L.B. Buck, personal communication; Liberles and Buck, 2006) were
grown in DMEM (Invitrogen) containing 5% FBS (Invitrogen) and 500 mg/ml
G-418 (Invitrogen) and maintained at 37C in an atmosphere of 5% CO2.
Cells were plated in 96-well plates at 50,000 cells/well and cotransfected
with the GPCR and reporter plasmid using Lipofectamine (Invitrogen) and
PLUS reagent (Invitrogen). The transfection media was replaced with ligand-
containing DMEM (200 ml/well) and cells were incubated for 36–48 hr 37C/
5% CO2. Care was taken to avoid exposure to bright, nonfiltered light. Each
plate was then wrapped in plastic wrap and incubated at 68C for 2 hr to
heat-inactivate native phosphatases. After transferring 100 ml aliquots from
each well to a fresh 96-well plate, 100 ml of an aqueous buffer containing
2 M diethanolamine bicarbonate and 1.2 mMmethylumbelliferone phosphate,
pH 10.0, was added to each well. Plates were imaged using a Perkin Elmer
Envision plate reader using optical settings for methylumbelliferone fluores-
cence, taking care to image all conditions to be compared on the same day
for a single receptor at the same time point after MUP addition. In every indi-
vidual experiment, the noncaged parent ligand (LE or Dyn-8) was evaluated
alongside the caged compound (CYLE or CYD8) at the same receptor and
used to normalize data across trials. cDNAs encoding human delta (OPRD1)
and human kappa opioid receptors (OPRK1) contained an N-terminal 3xHA
epitope tag (Missouri S&T cDNA Resource center, http://www.cdna.org) and
the murine mu opioid receptor (OPRM1) contained an N-terminal FLAG
epitope tag. Data shown reflect the average of six replicates run in parallel
for each condition.
Animal Handling and Slice Preparation
Animals were handled according to protocols that were approved by the
Harvard Standing Committee on Animal Care and are in accordance with
Federal guidelines. Postnatal day 22–29 Long-Evans rats were anesthetized
by inhalation of isoflurane and cardiac perfused with ice-cold ACSF contain-
ing 127 mM NaCl, 2.5 mM KCl, 25 mM NaHCO3, 1.25 mM NaH2PO4,
2.0 mM CaCl2, 1.0 mM MgCl2, and 25 mM glucose, equilibrated with
95% O2/5% CO2, osmolarity 307. Horizontal slices of locus coeruleus were
prepared in a cold choline-ACSF containing 25 mM NaHCO3, 1.25 mM
NaH2PO4, 2.5 mM KCl, 7 mM MgCl2, 25 mM glucose, 1 mM CaCl2, 110 mM
choline chloride, 11.6 mM ascorbic acid, and 3.1 mM pyruvic acid, and equil-
ibrated with 95%O2/5%CO2. Slices of 260 mm thickness were cut with a Leica
VT1000s (Leica Instruments, Nussloch, Germany) and transferred to a holding
chamber containing ACSF. Slices were incubated at 32C for 30–45 min and
then left at room temperature (20–22C) until recordings were performed.
Electrophysiology
All recordings were performed within 5 hr of slice cutting in a submerged
slice chamber perfused with ACSF warmed to 32C and equilibrated with
95% O2/5% CO2. Whole-cell recordings were made from LC neurons
visualized using Dodt gradient contrast. The LC was identified in horizontal
brainstem slices as a distinct, relatively translucent cluster of cells with
exceptionally large somata, typically 20–30 mm in diameter. For current-clamp
recordings and voltage-clamp recordings measuring K+ currents, patch
pipettes (open pipette resistance 1.6–2.2 MU) were filled with an internalsolution containing 135 mM KMeSO4, 5 mM KCl, 5 mM HEPES, 1.1 mM
EGTA, 4 mM MgATP, 0.3 mM Na2GTP, and 10 mM Na2creatine phosphate
(pH 7.25, osmolarity 286). For the experiments in Figures 4E and 6, 20 mM
Alexa 594 (Molecular Probes) was included in the internal solution.
Recordings weremade with an Axoclamp 200B amplifier (Axon Instruments,
Union City, CA). Data were filtered at 5 kHz and sampled at 10 kHz. Cells
were held at 55mV in voltage-clamp mode, and no current was injected in
current-clamp mode. Cells were rejected if holding currents exceeded
200 pA. Series and input resistance were measured throughout the experi-
ment, and recordings were discarded if series resistance exceeded 15 MU.
Series resistance was not compensated. Liquid junction potentials of
8mV were not corrected except when calculating the reversal potentials
in Figure 4. In these experiments, we only accepted recordings in which series
resistance was between 5 and 8 MU and compensated for whole-cell capac-
itance and series resistance by 60%–80%.
Pharmacology
In all experiments, the following pharmacological agents were used in the
extracellular solution at final concentrations of 10 mM CPP (Tocris), 10 mM
NBQX (Tocris), and 25 mM picrotoxin (Tocris). In some experiments, additional
agents were added, as indicated in the text: 2 mM naloxone (Tocris), 100 mM
carbenoxolone (Tocris), 3 mM thiorphan (Sigma), 20 mM bestatin (Sigma),
3.5 mM BaCl2 (Sigma), 1 mM TTX (Tocris), 1 mM 4-AP (Tocris), 300 mM
CdCl2 (Sigma), and 50 mM ZD7288 (Tocris).
UV Uncaging
For UV uncaging, we used a custom setup based on a BX51Wl microscope
(Olympus). The output of a 100 KHz pulsed q-switched UV laser (Model
3501, DPSS, Santa Clara, Ca) producing 800 mW of 354.7 nm light was
launched into a multimode, 200-mm-inner-diameter optical fiber with a numer-
ical aperture of 0.22 (OZ Optics, Ottawa, Ontario, Canada). The beam was
shuttered at the laser head (OZ Optics, part number HPUC-2,A3HP-355-M-
10BQ-1-SH) and collimated at the output of the fiber using either a factory-
(OZ Optics, part number HPUC0-2,A3HP-355-M-25BQ) or custom-built
collimator to produce a 10-mm-diameter beam. Laser pulses were controlled
by opening the shutter, waiting for mechanical vibrations in the fiber launch to
dampen, and then q-switching the laser on and off. Light power levels were
monitored with a PDA25K amplified photodiode (Thorlabs). Uncaging areas
were measured by imaging laser-evoked fluorescence from a thin layer of
an aqueous fluorescein solution that was sandwiched between two glass
coverslips and placed in the sample chamber.
For the experiments in Figures 2, 3B–3D, 4B–4D, and 5, the 10-mm-diam-
eter beam was focused using a planoconvex lens onto the back focal plane
of a 603 water-immersion, infinity-corrected objective with a numerical aper-
ture of 0.90 (Olympus) to produce a collimated beam of 124 mm in diameter.
Light intensity was attenuated to 25 mW, measured as a 10-mm-diameter
beam at the back aperture of the objective with the planoconvex lens removed
from the light path. An iris placed in the light path in a conjugate image plane
served as a field diaphragm. The iris was adjusted such that the diameter of the
area in the tissue exposed to UV light was either124 mm,73 mm,39 mm, or
18 mm, corresponding to the beam areas of 12 3 103 mm2, 4.2 3 103 mm2,
1.23 103 mm2, or 250 mm2, respectively, as indicated in the text. For the exper-
iments in Figures 3A and 4E, the beamwas launched directly into the objective
to produce a focused UV spot of 30 mm in diameter, and power was modu-
lated with neutral density filters to range from 1 mW to 91 mW, measured as
a 10-mm-diameter beam at the back aperture of the objective. In this optical
configuration, photolysis at light intensities >91 mW led to unstable record-
ings. For the experiments in Figure 6, the output from a multimode, 25-mm-
inner-diameter optical fiber with an numerical aperture of 0.13 (OZ Optics,
Ottawa, Ontario, Canada) was collimated to a 10-mm-diameter beam and
launched directly into the objective to produce a focused UV spot of 2 mm
in diameter at the sample. Power was modulated empirically to yield
a100 pA response at the soma. For the experiments in Figure S4, the output
from the 25 mm fiber was collimated to a 2.5-mm-diameter beam that was
focused using a planoconvex lens onto the back focal plane of the objective.
The field diaphragm was adjusted to produce a collimated beam of 10 mm in
diameter at the sample.Neuron 73, 249–259, January 26, 2012 ª2012 Elsevier Inc. 257
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Neurons in acute slices were loaded with 100 mm Alexa Fluor 594 via a patch
pipette, and images were taken using a custom-built two-photon microscope
and a Chameleon Ti-Sapphire laser tuned to 840 nm.
Data Analysis and Statistics
All data are expressed as the mean ± SEM. In the figures, average traces are
shown as themean (line) ± the SEM (shaded regions or bars). A two-tailed t test
was used to determine significance of differences across conditions in Figures
2 and 5. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found
with this article online at doi:10.1016/j.neuron.2011.11.016.
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